tbuckley/cabot-search huggingface dataset:
Antitumor properties of selenous acid in human prostate cancer cells
Authors: Reijko Sakurai, Kasif Ross, Carlos Guzman, Yanyuan Wu, Jaydutt V. Vadgama
Journal: Cancer Research (2005)

2290  Epidemiological studies and limited clinical trials data suggest that selenium may reduce the incidence of several cancers including prostate. The mechanisms by which selenium exerts its anti-cancer effects are under intense investigation. This problem is compounded by the knowledge that the chemo-prevention properties of different selenium compounds are different depending on the source and or chemical structure of selenium. Furthermore, we have limited understanding on the role of selenium on normal prostate cells compared to the cancerous prostate cells. We have selected a normal prostate cell line RWPE-1 and three different prostate cancer cell lines depending on their androgen receptor status and response to hormonal regulation. We tested the effect of seven different selenium compounds on these cells. The source of different selenium compounds were: yeast selenium, selenic acid, selenous acid, selenocystamine, selenomethionine, sodium selenite and sodium selenate. Growth inhibition studies showed that different selenium compounds had different effects on the growth of these cells. Three of the cancer cells (LNCaP, DU-145, and PC3) responded strongly to selenous acid, but not the normal prostate cells RWPE-1. Sodium selenite at low concentration induced growth inhibition of LNCaP and DU-145, but not of PC3 and normal prostate cells. Yeast selenium had no effect on the androgen receptor-positive cells LNCaP. In contrast, at low concentration of 0.5 μg/ml selenomethionine, selenocystamine, sodium selenate and selenic acid had no significant effect on all of three prostate cancer cells. Next, we examined the cellular pathways leading to apoptosis in response to different selenium compounds. Our results confirm that selenous acid induced-apoptosis involves a common pathway that results in the activation of caspase 9 and 7, and poly (ADP-ribose) polymerase (PARP) cleavage in LNCaP, DU-145 and PC3 human prostate cancer cells. In addition, selenous acid induced-apoptosis down regulated phosphor-Akt/PKB and GSK in PC3 cells. Selenous acid down regulated cyclin D1 in LNCaP and DU-145 cells. Selenous acid treated LNCaP cells up-regulated MAPK (ERK1/2) in a dose dependent manner. Inhibiting the MAP kinase pathway with PD98059, however, did not affect the extent of apoptosis induced by selenous acid, suggesting that the apoptotic signal was independent of ERK1/2. In summary, our data suggest that selenous acid is a more potent inhibitor of prostate tumor cell growth compared to sodium selenite, yeast selenium, selenomethionine, selenocystamine, sodium selenate and selenic acid. Selenous acid is equally effective as growth inhibitor of androgen-dependent and androgen-independent prostate cancer cells. This study provides evidence that Selenous acid at micro-molar concentration induces apoptosis and inhibition of cell proliferation in human prostate cancer cells, but not in normal prostate epithelial cells.
Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk Stratification
Authors: Aimaz Afrough, Rafee Talukder, Sarvari Venkata Yellapragada, Purnima Sravanti Teegavarapu, Martha P. Mims, Gustavo A. Rivero
Journal: Blood (2019)
Risk Factors for Central Nervous System (CNS) Relapse after Autologous Stem Cell Transplant (ASCT) in Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Yukie Terasaki, Hiroaki Shimizu, Yuri Miyazawa, Kohtaro Toyama, Hiromi Koiso, Akihiko Yokohama, Morio Matsumoto, Hidemi Ogura, Chiaki Naito, Norifumi Tsukamoto, Hiroshi Handa
Journal: Blood (2019)
PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels
Authors: Antonio Rueda Martin, Eleanor Williams, Rebecca E. Foulger, Sarah Leigh, Louise C. Daugherty, Olivia Niblock, Ivone U. S. Leong, Katherine R. Smith, Oleg Gerasimenko, Eik Haraldsdottir, Ellen Thomas, Richard H. Scott, Emma Baple, Arianna Tucci, Helen Brittain, Anna de Burca, Kristina Ibañez, Dalia Kasperaviciute, Damian Smedley, Mark Caulfield, Augusto Rendon, Ellen M. McDonagh
Journal: Nature Genetics (2019)
Take Control. Period. - Needs Assessment Leading to the Development of a Digital Quality Improvement Intervention Designed to Enhance Adherence to Tranexamic Acid and Iron Supplementation in Women with Heavy Menstrual Bleeding
Authors: Ying Ling, Filomena Meffe, Deborah Robertson, Jessica Petrucci, Georgina Floros, Paula D. James, Jeffrey Mosko, Michelle Sholzberg
Journal: Blood (2019)
Unique Regulatory Pathways Dictate the Translational Program in Hematopoietic Stem and Progenitor Cells
Authors: Harold K. Elias, Christina Spevak, Lavanya Kannan, Mohamed A.E. Ali, Gaelle H Martin, Shanmugapriya Selvaraj, William S Eng, Guangjie Zhao, Amanda Ernlund, Vinagolu Rajasekhar, Carolien M Woolthuis, Robert J Schneider, Christopher Y. Park
Journal: Blood (2019)
Impaired Right Ventricular–Vascular Coupling in Young Adults Born Preterm
Authors: Ashley Mulchrone, Alessandro Bellofiore, Johannes M. Douwes, Neal Duong, Arij G. Beshish, Gregory P. Barton, Christopher J. Francois, Marlowe W. Eldridge, Kara N. Goss, Naomi C. Chesler
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

airways.Although it was beyond the scope of our study to investigate the etiology of reduced TAC, our data suggest that the same remodeling process that occurs in the TBs may extend to the larger airways and be measured by MDCT.We acknowledge that this was a retrospective study, and therefore it was not possible to access preoperative MDCT images to compare the relationship with TAC using clinical and explant CT images.The lung specimens have no chest wall and MDCT images were acquired at a fixed lung volume, without any motion artifacts, and therefore an increased number of airways may be quantified in specimen MDCT.MDCT LAA 950 measurements may also be overestimated in lung specimens due to a lack of blood flow/volume.However, our primary objective was to investigate the association between TAC and TBs, which are not impacted by the lack of blood flow/volume.We also note that although we used random sampling to obtain cores for micro-CT analysis from donor lungs, we used selective sampling to avoid regions of severe emphysema in the COPD lungs, as such regions have been reported to lack TBs (1, 2).This may have resulted in biased estimates of the number of TBs in the COPD lungs and may partially explain the lack of correlation between TBs and TAC in COPD.In conclusion, this study shows that TAC is associated with both the number of TBs and the distortion/remodeling that occurs in the TBs that remain in COPD lungs.Thus, TAC may be used as an imaging biomarker (9) to estimate the number and distortion of small airways and may provide a valuable outcome measure for clinical trials of new therapies aimed at the prevention and treatment of small airways disease.
INNV-20. A SYSTEMATIC REVIEW OF TUMOR TREATING FIELDS THERAPY FOR PRIMARY FOR RECURRENT AND GLIOBLASTOMA
Authors: Pavan Shah, Taija White, Carrie Price, Debraj Mukherjee
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioblastoma is an aggressive primary central nervous system malignancy with poor prognosis and limited treatment options. Tumor treating fields (TTFs) are a novel treatment modality utilizing alternating electric fields that have demonstrated promise in randomized clinical trials for primary and recurrent glioblastomas. In addition to these studies, a multitude of smaller investigations have been performed examining their efficacy in a variety of combination therapies. This systematic review of available literature aims to summarize and evaluate the efficacy and safety of TTFs for primary and recurrent glioblastoma patients. METHODS A systematic review of the literature was performed according to PRISMA guidelines from database inception through 2/27/2019. Databases queried include PubMed, Embase, Cochrane, Scopus, Web of Science, and ClinicalTrials.gov. 856 unique studies were initially identified in this search, 9 of which met final inclusion criteria. 2 authors independently performed the screening and data extraction of the studies. RESULTS Excluding historical controls, 1569 patients were identified in these studies, 1191 of which received TTFs therapy. TTFs were evaluated in single-arm clinical trials (n = 2), randomized clinical trials (n = 2), and retrospective studies (n = 5). These 9 studies are presented based on treatments provided, baseline patient characteristics, and patient outcomes. No adverse events appear to be associated with TTFs other than adverse skin reactions. Given the heterogeneity in the presented studies, a quantitative meta-analysis was not performed. CONCLUSIONS TTFs are a novel treatment modality that have demonstrated safety and efficacy in a number of settings and study designs. However, further investigation is needed to continue characterizing treatment outcomes and assessing TTFs interactions with various drug regimens.
Inflammation as a Treatment Target after Acute Myocardial Infarction
Authors: L. Kristin Newby
Journal: New England Journal of Medicine (2019)

Inflammation is widely believed to play a central role in the pathogenesis of atherosclerosis and acute coronary events.1,2 Although treatments with proven benefits for secondary prevention of coronary artery disease (e.g., statins and aspirin) appear to have salutary effects on inflammation, the identification of an effective treatment specifically targeting inflammation has been elusive.3 The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) provided encouragement that targeting inflammation may be an effective treatment in chronic coronary artery disease. In CANTOS, canakinumab, a monoclonal antibody inhibiting interleukin-1β, reduced the level of high-sensitivity C-reactive protein and resulted in a modestly lower risk of the composite . . .
Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device
Authors: Estelle Beguin, Michael D. Gray, Keiran A. Logan, Heather Nesbitt, Yingjie Sheng, Sukanta Kamila, Lester C. Barnsley, Luca Bau, Anthony P. McHale, John F. Callan, Eleanor Stride
Journal: Journal of Controlled Release (2019)

Recent pre-clinical studies have demonstrated the potential of combining chemotherapy and sonodynamic therapy for the treatment of pancreatic cancer. Oxygen-loaded magnetic microbubbles have been explored as a targeted delivery vehicle for this application. Despite preliminary positive results, a previous study identified a significant practical challenge regarding the co-alignment of the magnetic and ultrasound fields. The aim of this study was to determine whether this challenge could be addressed through the use of a magnetic-acoustic device (MAD) combining a magnetic array and ultrasound transducer in a single unit, to simultaneously concentrate and activate the microbubbles at the target site. in vitro experiments were performed in tissue phantoms and followed by in vivo treatment of xenograft pancreatic cancer (BxPC-3) tumours in a murine model. In vitro, a 1.4-fold (p < .01) increase in the deposition of a model therapeutic payload within the phantom was achieved using the MAD compared to separate magnetic and ultrasound devices. In vivo, tumours treated with the MAD had a 9% smaller mean volume 8 days after treatment, while tumours treated with separate devices or microbubbles alone were respectively 45% and 112% larger. This substantial and sustained decrease in tumour volume suggests that the proposed drug delivery approach has the potential to be an effective neoadjuvant therapy for pancreatic cancer patients.
High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster
Authors: Sakshi Jasra, Orsi Giricz, Rachel Zeig-Owens, David Goldfarb, Angelica Barreto-Galvez, Kith Pradhan, Jiahao Chen, Gaurav S Choudhary, Srinivas Aluri, Tushar D Bhagat, Aditi Shastri, Victor Thiruthuvanathan, Hiroki Goto, Jeannine Gerhardt, Shanisha Gordon, Arul Veerappan, Syed Hissam Haider, Matthias Bartenstein, George Nwankwo, Ola Landgren, Michael Weiden, Frederick Fletcher, Lee Greenberger, Benjamin L. Ebert, Ulrich G. Steidl, Britta Will, Anna Nolan, David Prezant, Advaitha Madireddy, Amit Verma
Journal: Blood (2019)
SURG-19. REORGANIZATION OF LANGUAGE ENABLES SAFE RESECTION OF TUMORS IN AND AROUND BROCA’S AREA
Authors: Emma Holmes, Keith Kerr, Cihan Kadipasaoglu, Nitin Tandon
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Since its discovery in the 1800s, Broca’s area has been viewed as a critical node for language production. Previously, pathologies in this area have been considered unresectable due to concern for producing iatrogenic language production deficits. Emerging literature suggests that although acute lesions in this area can cause widespread deficits, slow growing lesions are less correlated with these deficits due to cortical language reorganization. Based on this data, we managed a cohort with Broca’s area lesions with surgical resection using awake intra-operative language mapping. METHODS All 150 awake craniotomies performed by the senior author over a twelve-year period (2006–2017) at a single institution were reviewed. For each patient the imaging was carefully evaluated to localize the neoplasm relative to pars triangularis or pars opercularis in the language dominant hemisphere. Language dominance was confirmed using WADA testing or fMRI. All patients underwent cortical language mapping using a battery of tasks coupled with cortical stimulation. RESULTS A total of 31 surgeries in 29 patients (65.5% male, 86.2% righthanded) were identified. The average age was 41. Patients presented with seizures (64.5%), speech difficulties (35.5%) or headaches (19.4%). A gross or near total resection was achieved in 26/29 (89.7%) of patients. Pathological evaluation revealed grade 2 gliomas (8), grade 3 gliomas (13) and glioblastoma (9). Post-operatively, 8 (25.8%) patients had new or worsening speech deficits, all of which resolved to baseline at follow-up. CONCLUSION Broca’s area lesions can be safely resected in patients using an awake craniotomy technique with language mapping. In our series, the majority of patients had gross or near total resections, few patients had new deficits, and none had permanent new deficits. Considering the increasing evidence in favor of cytoreduction to manage glial neoplasms, this technique should be employed routinely for pathologies in this area to optimize patient outcomes.
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Authors: Richard R. Furman, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan M. O'Brien, John C. Byrd
Journal: Blood (2019)
Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
Authors: Caitlin L. Costello, Tara K. Gregory, Syed Abbas Ali, Jesus G. Berdeja, Krina K. Patel, Nina D. Shah, Eric Ostertag, Chris Martin, Majid Ghoddusi, Devon J Shedlock, Matthew A. Spear, Robert Z. Orlowski, Adam D. Cohen
Journal: Blood (2019)
Kupffer Cells Mediate Systemic Antifungal Immunity
Authors: Carolina Coelho, Rebecca A. Drummond
Journal: Trends in Immunology (2019)

Patients with liver dysfunction have increased susceptibility to fungal infections. A recently published article (Sun et al.) describes the potential mechanism underlying this association, which maps to the antifungal activity of liver-resident Kupffer cells. This research highlights the importance of understanding tissue-specific immune responses in disease pathogenesis.
Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage
Authors: Dacia D. C. A. Henriquez, Camila Caram-Deelder, Saskia le Cessie, Joost J. Zwart, Jos J. M. van Roosmalen, Jeroen C. J. Eikenboom, Cynthia So-Osman, Leo M. G. van de Watering, Jaap Jan Zwaginga, Ankie W. M. M. Koopman-van Gemert, Kitty W. M. Bloemenkamp, Johanna G. van der Bom
Journal: JAMA Network Open (2019)

Early plasma transfusion for women with severe postpartum hemorrhage (PPH) is recommended to prevent coagulopathy. However, there is no comparative, quantitative evidence on the association of early plasma transfusion with maternal outcomes.To compare the incidence of adverse maternal outcomes among women who received plasma during the first 60 minutes of persistent PPH vs women who did not receive plasma for similarly severe persistent PPH.This multicenter cohort study used a consecutive sample of women with persistent PPH, defined as PPH refractory to first-line measures to control bleeding, between January 1, 2011, and January 1, 2013. Time-dependent propensity score matching was used to select women who received plasma during the first 60 minutes of persistent PPH and match each of them with a woman who had shown the same severity and received the same treatment of PPH but who had not received plasma at the moment of matching. Transfusions were not guided by coagulation tests. Statistical analysis was performed from June 2018 to June 2019.Transfusion of plasma during the first 60 minutes of persistent PPH vs no or later plasma transfusion.Incidence of adverse maternal outcomes, defined as a composite of death, hysterectomy, or arterial embolization.This study included 1216 women (mean [SD] age, 31.6 [5.0] years) with persistent PPH, of whom 932 (76.6%) delivered vaginally and 780 (64.1%) had PPH caused by uterine atony. Seven women (0.6%) died because of PPH, 62 women (5.1%) had a hysterectomy, and 159 women (13.1%) had arterial embolizations. Among women who received plasma during the first 60 minutes of persistent PPH, 114 women could be matched with a comparable woman who had not received plasma at the moment of matching. The incidence of adverse maternal outcomes was similar between the women, with adverse outcomes recorded in 24 women (21.2%) who received early plasma transfusion and 23 women (19.9%) who did not receive early plasma transfusion (odds ratio, 1.09; 95% CI, 0.57-2.09). Results of sensitivity analyses were comparable to the primary results.In this cohort study, initiation of plasma transfusion during the first 60 minutes of persistent PPH was not associated with adverse maternal outcomes compared with no or later plasma transfusion, independent of severity of PPH.
Ocular injuries caused by less-lethal weapons in France
Authors: Aurore Chauvin, Jean-Louis Bourges, Jean-François Korobelnik, Michel Paques, Pierre Lebranchu, Frederic Villeroy, Christophe Chiquet, Carl Arndt, Pierre Fournier, Max Villain, Frederic Mouriaux, Gilles Thuret, Isabelle Cochereau, Carole Burillon, Laurent Kodjikian, José-Alain Sahel, Alain Gaudric, Bahram Bodaghi
Journal: The Lancet (2019)
Erratum to: STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5-CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN GLIOMA STEM CELLS
Authors: Subhas Mukherjee, Cheryl Olson, Bilge Dundar, Nitya Sharma, Steven Markwell, Daniel Brat
Journal: Neuro-Oncology (2021)
Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry
Authors: Timothy Devos, Violaine Havelange, Koen Theunissen, Stef Meers, Fleur Samantha Benghiat, Alain Gadisseur, Gaëtan Vanstraelen, Marc André, Benjamin Bailly, Nikki Granacher, Philippe Lewalle, Ann De Becker, Koen Van Eygen, Marie Lejeune, Dries Deeren, Gianfilippo Nifosi, Agnes Triffet, Inge Vrelust, Julie Bekaert, Michael Beck, Dominik Selleslag
Journal: Blood (2019)
Phonocardiographic Features of Atrial Septal Defect
Authors: ROBERT EISENBERG, HERBERT N. HULTGREN
Journal: Circulation (1959)

The heart sounds of 20 patients with uncomplicated atrial septal defect have been analyzed, and the deviations from a normal control group were noted. Following complete closure of the defect 11 patients have been restudied, and the changes produced in the heart sounds by closure of the defect are discussed. By comparison of pre-operative and postoperative heart sounds and electrocardiograms it has been possible to ascribe some abnormalities of the heart sounds to the presence of the left-to-right shunt, and some to the presence of delayed electrical depolarization of the right ventricle.
Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab
Authors: Neetha Parameswaran, Xiaoxian Zhao, Juraj Bodo, Lisa Durkin, Yvonne Parker, Daniel Lindner, Eric D. Hsi, Deepa Jagadeesh
Journal: Blood (2019)
A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
Authors: Chenggong Li, Heng Mei, Yu Hu, Tao Guo, Lin Liu, Huiwen Jiang, Lu Tang, Yaohui Wu, Lisha Ai, Jun Deng, Dan Jin
Journal: Blood (2019)
Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement
Authors: Mark Wunderlich, Jing Chen, Eric O'Brien, Nicole Manning, Christina Sexton, Luke Byerly, John P Perentesis, Benjamin Mizukawa, James C Mulloy
Journal: Blood (2019)
Deciphering the Causal Diagnosis of Hydrops Fetalis or Unexplained Fetal Anemia Using Targeted Next Generation and Exome Sequencing
Authors: Julie Galimand, Helene Bourdeau, Odile Fenneteau, Sophie Dreux, Nathalie Couque, Severine Drunat, Serge Pissard, Thierry Leblanc, Anne Lambilliotte, Catherine Thong Vanh, Caroline Alby, jelena-Hélène martinovic-Bouriel, Chloé Quelin, Mohandas Narla, Anne Cortey, Lydie Da Costa
Journal: Blood (2019)
Invincible arrogance--and patients suffer
Authors: A R Kemp
Journal: BMJ (1981)

sprinters lack stamina, but I imagine that no one would question their cardiopulmonary fitness-while in training.I am also worried by the modified physical fitness index, as this fails to take account of the resting pulse rate.Surely a formula based on percentage increase over resting rate at two, five, and 10 minutes would seem more reasonable, since the normal resting pulse rate can vary from the 40s to the 90s at least-or does a naturally slow pulse rate confer a fitness advantage ?Interestingly, Lieutenant-ColonelPearn referred to Zatopek's fitness index of 172; he was a distance runner with a resting pulse rate of about 40 per minute.But I wonder how Zatopek would have fared on the squash court, where explosive bursts of energy are required, or in gymnastics, in which a completely different sort of fitness and body control is demanded, or in the swimming pool.He certainly would have been